Prosecution Insights
Last updated: April 19, 2026
Application No. 17/685,601

BIO-PRODUCTION OF LENTIVIRAL VECTORS

Non-Final OA §112
Filed
Mar 03, 2022
Examiner
NGUYEN, QUANG
Art Unit
1631
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Csl Behring Gene Therapy Inc.
OA Round
3 (Non-Final)
38%
Grant Probability
At Risk
3-4
OA Rounds
3y 11m
To Grant
91%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allow Rate
280 granted / 734 resolved
-21.9% vs TC avg
Strong +53% interview lift
Without
With
+52.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
65 currently pending
Career history
799
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
37.9%
-2.1% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
27.8%
-12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 734 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/16/2025 has been entered. Claims 1-13 and amended claims 16-20 are pending in the present application, and they are examined on the merits herein. Response to Amendment 1. The rejection under 35 U.S.C. 102(a)(2) as being anticipated by Hirai et al (US 8,912,315) was withdrawn in light of currently amended claims 16-20. 2. The rejection under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, for Scope of Enablement was withdrawn in light of currently amended claim 16 and in favor of the New Matter rejection below. Claim Rejections - 35 USC § 112 (New Matter) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Amended claims 16-18 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Amended claim 16 recites the limitation “wherein each of the first DNA fragments comprises a nucleotide having at least 80% identity to SEQ ID NO: 1”, while amended claims 17-18 recite the limitation “A lentiviral vector comprising the recombinant plasmid of claim 1”. It is noted that claim 1 is drawn to a recombinant plasmid comprising a vector cassette having a nucleotide sequence having at least 85% identity with the nucleotide of SEQ ID NO: 2, wherein the vector cassette encodes a lentiviral vector backbone; and wherein the recombinant plasmid comprises a nucleotide sequence having at least 80% identity with the nucleotide sequence of SEQ ID NO: 1. Claim 16 encompasses a stable producer cell line, the stable producer cell line generated by: transfecting a packaging cell line selected from the group consisting of a GPRG packaging cell line, a GPRGT packaging cell line, and a GPRT-G packaging cell line with a concatemeric array comprising: (i) first DNA fragments obtained from the recombinant plasmid of claim 1; and (ii) second DNA fragments obtained from a bleomycin antibiotic resistance cassette; wherein a molar ratio of the first DNA fragments to the second DNA fragments ranges from about 25:1 to about 1:25, and wherein each of the first DNA fragments comprises a nucleotide sequence having at least 80% identity to SEQ ID NO: 1 (e.g., 85%, 90%, 95%, 97%, or 100% SEQ ID NO: 1). Claims 17-18 encompass a lentiviral comprising the recombinant plasmid of claim 1 which is a recombinant plasmid comprising a nucleotide sequence having at least 80% identity with the nucleotide sequence of SEQ ID NO: 1 (e.g., 85%, 90%, 95%, 97%, or 100% SEQ ID NO: 1). SEQ ID NO: 1 is the 6565-nucleotide sequence of pUC57-TL20C (a human immunodeficiency virus type 1 (HIV-1) based third generation, self-inactivating (SIN) lentiviral transfer vector plasmid) which map is depicted diagrammatically below (paragraphs [0076]-[0077]; Fig. 11; and Sequence listing). PNG media_image1.png 405 458 media_image1.png Greyscale The as-filed specification does not have a written support for these limitations. As an initial matter, claims 16-18 have been introduced in the Amendment filed on 10/16/2025, so the claims themselves are not part of the original disclosure. 37 CFR § 1.115(a)(2). “New or amended claims which introduce elements or limitations that are not supported by the as-filed disclosure violate the written description requirement. . . . While there is no in haec verba requirement, newly added claims or claim limitations must be supported in the specification through express, implicit, or inherent disclosure. . . . The fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, applicant was in possession of the invention as now claimed.” MPEP § 2163, part (I)(B); see also MPEP § 2163.02. In this case, the original specification does not convey the particular invention recited in claims 16-18 with reasonable clarity to skilled artisans. “The trouble is that there is no such disclosure, easy though it is to imagine it.” MPEP § 2163.05, part (II) (quoting In re Ruschig, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967)). In the Amendment filed on 10/16/2025 (first paragraph at page 5), Applicant simply stated that no new matter has been added, without citing anywhere in the as-filed specification as an alleged written support for the above limitations. The originally filed specification stated “In another aspect of the present disclosure is a method of producing a stable producer cell line comprising: (a) synthesizing a lentiviral vector by cloning one or more genes into a plasmid as described herein (e.g. pUC57-TL20c; (b) generating DNA fragments from the synthesized lentiviral vector; (c) forming a concatemeric array from the generated DNA fragments of the synthesized lentiviral vector and from DNA fragments from an antibiotic resistance cassette plasmid; (d) transfecting a GPR, GPRG, GPRT, GPRGT or GPRT-G packing cell line or a derivative thereof with the formed concatemeric array; and (e) isolating one or more stable producer cell line clones. In some embodiments, the method further comprises inducing the stable producer cell line to produce the lentiviral vector” (paragraph [0023]). The as-filed specification also discloses that with reference to FIG. 14 as depicted diagrammatically below for forming a concatemeric array, the DNA fragments from a lentiviral transfer vector plasmid (based on pUC57-TL20c) (step 100) and an antibiotic resistance cassette plasmid are generated (step 110), wherein the vector plasmid is digested with the restriction enzyme Sfil (paragraphs [0105]-[0106]; and Fig. 14). PNG media_image2.png 413 388 media_image2.png Greyscale On the basis of the above disclosures, the originally filed specification does not have a written support at least for the concept of generating first DNA fragments obtained from the recombinant plasmid of claim 1 comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 1 (the 6565-nucleotide sequence of pUC57-TL20C), wherein each of the first DNA fragments comprises a nucleotide sequence having at least 80% identity (e.g., 85%, 90%, 95%, 99%, or even 100%) to SEQ ID NO: 1 to form a concatemeric array for transfection of a packaging cell line to produce a lentiviral vector as encompassed by currently amended claim 16. As a result, the originally filed specification also does not have a written support for a lentiviral vector comprising the recombinant plasmid vector of claim 1 comprising a nucleotide sequence having at least 80% identity (e.g., 85%, 90%, 95%, 99%, or even 100%) to SEQ ID NO: 1 as encompassed by currently amended claims 17-18. There is no teaching whatsoever that a generated lentiviral vector whose genome comprising the 6565-nucleotide sequence of pUC57-TL20C. The fact that the person of ordinary skill in the art could have carried out the claimed invention without undue experimentation based on applicants’ disclosure is inadequate to meet this requirement. “The Federal Circuit has pointed out that, under United States law, a description that merely renders a claimed invention obvious may not sufficiently describe the invention for the purposes of the written description requirement of 35 U.S.C. 112.” MPEP § 2163, part (I)(A). Therefore, given the lack of sufficient guidance provided by the originally filed specification, it would appear that Applicants did not contemplate or have possession of invention as now claimed at the time the application was filed. Conclusion Claims 1-13 and 19-20 are allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Quang Nguyen, Ph.D., at (571) 272-0776. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s SPE, James Douglas (Doug) Schultz, Ph.D., may be reached at (571) 272-0763. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1631; Central Fax No. (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO’s Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll-free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO’s Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO’s PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. /QUANG NGUYEN/Primary Examiner, Art Unit 1631 Sequence 2, Patent No. 10138495 Synthetic: TL20C vector backbone Query Match 59.4%; Score 3901; Length 3901; Best Local Similarity 100.0%; Matches 3901; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Qy 1 GGCCGCCTCGGCCAAACAGCCCTTGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTG 60 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1 GGCCGCCTCGGCCAAACAGCCCTTGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTG 60 Qy 61 AAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACT 120 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 61 AAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACT 120 Qy 121 CCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGA 180 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 121 CCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGA 180 Qy 181 AAAGTGAAAGTCGAGTTTACCAGTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTT 240 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 181 AAAGTGAAAGTCGAGTTTACCAGTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTT 240 Qy 241 ACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGA 300 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 241 ACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGA 300 Qy 301 TAGAGAAAAGTGAAAGTCGAGCTCGCCATGGGAGGCGTGGCCTGGGCGGGACTGGGGAGT 360 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 301 TAGAGAAAAGTGAAAGTCGAGCTCGCCATGGGAGGCGTGGCCTGGGCGGGACTGGGGAGT 360 Qy 361 GGCGAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGG 420 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 361 GGCGAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGG 420 Qy 421 TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 480 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 421 TTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 480 Qy 481 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 540 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 481 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT 540 Qy 541 AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGA 600 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 541 AACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGA 600 Qy 601 ACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTG 660 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 601 ACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTG 660 Qy 661 CTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGA 720 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 661 CTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGA 720 Qy 721 CTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAA 780 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 721 CTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAA 780 Qy 781 TTAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAA 840 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 781 TTAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAA 840 Qy 841 AACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATACTGGCCTGTTAG 900 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 841 AACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATACTGGCCTGTTAG 900 Qy 901 AAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGAT 960 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 901 AAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGAT 960 Qy 961 CAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGA 1020 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 961 CAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGA 1020 Qy 1021 TAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTA 1080 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1021 TAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTA 1080 Qy 1081 AGAAAAAAGCACAGCAAGCAGCAGGATCTTCAGACCTGGAAATTCCCTACAATCCCCAAA 1140 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1081 AGAAAAAAGCACAGCAAGCAGCAGGATCTTCAGACCTGGAAATTCCCTACAATCCCCAAA 1140 Qy 1141 GTCAAGGAGTAGTAGAATCTATGAATAAAGAATTAAAGAAAATTATAGGACAGGTAAGAG 1200 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1141 GTCAAGGAGTAGTAGAATCTATGAATAAAGAATTAAAGAAAATTATAGGACAGGTAAGAG 1200 Qy 1201 ATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGTATTCATCCACAATTTTAAAA 1260 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1201 ATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGTATTCATCCACAATTTTAAAA 1260 Qy 1261 GAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAG 1320 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1261 GAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAG 1320 Qy 1321 ACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATT 1380 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1321 ACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATT 1380 Qy 1381 ACAGGGACAGCAGAAATCCACTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAAG 1440 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1381 ACAGGGACAGCAGAAATCCACTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAAG 1440 Qy 1441 GGGCAGTAGTAATACAAGATAATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGA 1500 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1441 GGGCAGTAGTAATACAAGATAATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGA 1500 Qy 1501 TCATTAGGGATTATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATG 1560 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1501 TCATTAGGGATTATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATG 1560 Qy 1561 AGGATTAGAACATGGAAAAGTTTAGTAAAACACCATAAGGAGGAGATATGAGGGACAATT 1620 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1561 AGGATTAGAACATGGAAAAGTTTAGTAAAACACCATAAGGAGGAGATATGAGGGACAATT 1620 Qy 1621 GGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA 1680 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1621 GGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA 1680 Qy 1681 CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 1740 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1681 CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGT 1740 Qy 1741 TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 1800 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1741 TCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGG 1800 Qy 1801 TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 1860 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1801 TACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA 1860 Qy 1861 TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 1920 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1861 TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA 1920 Qy 1921 GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 1980 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1921 GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCT 1980 Qy 1981 CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 2040 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1981 CTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTC 2040 Qy 2041 TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 2100 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2041 TGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA 2100 Qy 2101 CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 2160 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2101 CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAG 2160 Qy 2161 AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 2220 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2161 AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGC 2220 Qy 2221 TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 2280 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2221 TGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTT 2280 Qy 2281 TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 2340 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2281 TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGA 2340 Qy 2341 CCCACCTCCCAACCCCGAGGGGACCGAGCTCAAGCTTCGAACGCGTGCGGCCGCATCGAT 2400 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2341 CCCACCTCCCAACCCCGAGGGGACCGAGCTCAAGCTTCGAACGCGTGCGGCCGCATCGAT 2400 Qy 2401 GCCGTAGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTA 2460 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2401 GCCGTAGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTA 2460 Qy 2461 AAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATCCCTGCAGG 2520 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2461 AAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATCCCTGCAGG 2520 Qy 2521 CATTCAAGGCCAGGCTGGATGTGGCTCTGGGCAGCCTGGGCTGCTGGTTGATGACCCTGC 2580 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2521 CATTCAAGGCCAGGCTGGATGTGGCTCTGGGCAGCCTGGGCTGCTGGTTGATGACCCTGC 2580 Qy 2581 ACATAGCAGGGGGTTGGATCTGGATGAGCACTGTGCTCCTTTGCAACCCAGGCCGTTCTA 2640 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2581 ACATAGCAGGGGGTTGGATCTGGATGAGCACTGTGCTCCTTTGCAACCCAGGCCGTTCTA 2640 Qy 2641 TGATTCTGTCATTCTAAATCTCTCTTTCAGCCTAAAGCTTTTTCCCCGTATCCCCCCAGG 2700 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2641 TGATTCTGTCATTCTAAATCTCTCTTTCAGCCTAAAGCTTTTTCCCCGTATCCCCCCAGG 2700 Qy 2701 TGTCTGCAGGCTCAAAGAGCAGCGAGAAGCGTTCAGAGGAAAGCGATCCCGTGCCACCTT 2760 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2701 TGTCTGCAGGCTCAAAGAGCAGCGAGAAGCGTTCAGAGGAAAGCGATCCCGTGCCACCTT 2760 Qy 2761 CCCCGTGCCCGGGCTGTCCCCGCACGCTGCCGGCTCGGGGATGCGGGGGGAGCGCCGGAC 2820 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2761 CCCCGTGCCCGGGCTGTCCCCGCACGCTGCCGGCTCGGGGATGCGGGGGGAGCGCCGGAC 2820 Qy 2821 CGGAGCGGAGCCCCGGGCGGCTCGCTGCTGCCCCCTAGCGGGGGAGGGACGTAATTACAT 2880 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2821 CGGAGCGGAGCCCCGGGCGGCTCGCTGCTGCCCCCTAGCGGGGGAGGGACGTAATTACAT 2880 Qy 2881 CCCTGGGGGCTTTGGGGGGGGGCTGTCCCCGTGAGCTCCCCAGATCTGCTTTTTGCCTGT 2940 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2881 CCCTGGGGGCTTTGGGGGGGGGCTGTCCCCGTGAGCTCCCCAGATCTGCTTTTTGCCTGT 2940 Qy 2941 ACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAAC 3000 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 2941 ACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAAC 3000 Qy 3001 CCACTGCTTAAGCCTCAATAAAGCTTCAGCTGCTCGAGCTAGCAGATCTTTTTCCCTCTG 3060 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3001 CCACTGCTTAAGCCTCAATAAAGCTTCAGCTGCTCGAGCTAGCAGATCTTTTTCCCTCTG 3060 Qy 3061 CCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGA 3120 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3061 CCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGGA 3120 Qy 3121 AATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACAT 3180 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3121 AATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACAT 3180 Qy 3181 ATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACAT 3240 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3181 ATGGGAGGGCAAATCATTTAAAACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACAT 3240 Qy 3241 ATGCCCATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAGAGGTCATCAGTATATGA 3300 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3241 ATGCCCATATGCTGGCTGCCATGAACAAAGGTTGGCTATAAAGAGGTCATCAGTATATGA 3300 Qy 3301 AACAGCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGATTT 3360 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3301 AACAGCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTAGATTT 3360 Qy 3361 TTTTTATATTTTGTTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACATG 3420 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3361 TTTTTATATTTTGTTTTGTGTTATTTTTTTCTTTAACATCCCTAAAATTTTCCTTACATG 3420 Qy 3421 TTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCCCTCTTC 3480 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3421 TTTTACTAGCCAGATTTTTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTCCCTCTTC 3480 Qy 3481 TCTTATGGAGATCCCTCGACCTGCAGCCCAAGCTTGGCGTAATCATGGTCATAGCTGTTT 3540 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3481 TCTTATGGAGATCCCTCGACCTGCAGCCCAAGCTTGGCGTAATCATGGTCATAGCTGTTT 3540 Qy 3541 CCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAG 3600 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3541 CCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAG 3600 Qy 3601 TGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTG 3660 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3601 TGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTG 3660 Qy 3661 CCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCGGATCCGCATCTCAATTAGTCAGCAA 3720 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3661 CCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCGGATCCGCATCTCAATTAGTCAGCAA 3720 Qy 3721 CCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATT 3780 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3721 CCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATT 3780 Qy 3781 CTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCT 3840 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3781 CTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCT 3840 Qy 3841 CTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGC 3900 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 3841 CTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGC 3900 Qy 3901 T 3901 | Db 3901 T 3901
Read full office action

Prosecution Timeline

Mar 03, 2022
Application Filed
Feb 13, 2025
Non-Final Rejection — §112
May 16, 2025
Response Filed
Jul 17, 2025
Final Rejection — §112
Oct 12, 2025
Request for Continued Examination
Oct 14, 2025
Response after Non-Final Action
Oct 16, 2025
Response Filed
Dec 02, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12454689
INTEGRATION OF MESA RECEPTORS AND PROMOTORS TO IMPLEMENT CUSTOMIZED CELLULAR FUNCTION
2y 5m to grant Granted Oct 28, 2025
Patent 12454702
MINIGENE THERAPY
2y 5m to grant Granted Oct 28, 2025
Patent 12448426
CHIMERIC ANTIGEN RECEPTORS WITH MYD88 AND CD40 COSTIMULATORY DOMAINS
2y 5m to grant Granted Oct 21, 2025
Patent 12385048
CONSTRUCT AND SEQUENCE FOR ENHANCED GENE EXPRESSION
2y 5m to grant Granted Aug 12, 2025
Patent 12371474
RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING BIETTI CRYSTALLINE DYSTROPHY
2y 5m to grant Granted Jul 29, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
38%
Grant Probability
91%
With Interview (+52.7%)
3y 11m
Median Time to Grant
High
PTA Risk
Based on 734 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month